Immunosyn Execs Hit With $20M Insider Trading Suit

Law360, New York (August 2, 2011, 5:13 PM EDT) -- Executives at San Diego biotechnology firm Immunosyn Corp. hyped an experimental HIV drug, raising $20 million from investors, then sold their shares without disclosing that the drug's approval process was on hold, regulators claimed Monday in an Illinois insider trading suit.

The U.S. Securities and Exchange Commission's suit names Immunosyn CEO Stephen Ferrone and Chief Financial Officer Douglas McClain Jr. as defendants and seeks disgorgement, civil penalties and an order blocking them from serving as an officer or director of a publicly traded company.

"From 2006...
To view the full article, register now.




Case Information

Case Title

Securities And Exchange Commission v. Ferrone et al

Case Number



Illinois Northern

Nature of Suit



Honorable Jeffrey T. Gilbert

Date Filed

August 1, 2011

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.